BioMed Central retracting 43 papers for fake peer review

bmc logoBioMed Central is retracting 43 papers, following their investigation into 50 papers that raised suspicions of fake peer review, possibly involving third-party companies selling the service.

In November 2014 we wrote about fake peer reviews for Nature; at that point there had been about 110 retractions across several journals. The addition of 16 retractions by Elsevier for the same reason, and today’s 43 from BMC, brings retractions resulting from the phenomenon up to about 170.

BMC has also contacted institutions regarding 60 additional papers that were rejected for publication, but seem to be part of the same kind of scam. Regarding the third-party agents, BMC senior editor of scientific integrity Elizabeth Moylan writes: Continue reading BioMed Central retracting 43 papers for fake peer review

David Vaux: Nature’s decision to add double-blind peer review is good, but could be better

David Vaux, a cell biologist at the Walter + Eliza Hall Institute of Medical Research in Melbourne, explains how Nature could do more to remove bias from the peer review process. He previously wrote about his decision to retract a paper.

vaux
David Vaux

Last week, Nature announced that they are to offer authors of papers submitted to Nature or the monthly Nature research journals the option of having their manuscripts assessed by double-blind peer review, in which reviewers are blinded to the identity of authors and their institutions. Until now, papers sent to Nature, and most other journals, have been reviewed by a single-blind process, in which the reviewers know the identities and affiliations of the authors, but the authors are not told who the reviewers are. The goal of double-blind peer review is for submitted papers to be judged on their scientific merit alone, and thus to reduce publication bias.

While Nature should be applauded for this move, the way they have implemented it leaves room for improvement.

Continue reading David Vaux: Nature’s decision to add double-blind peer review is good, but could be better